Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

229.25 +1.01 (+0.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 754,686
Open 226.58
Bid (Size) 118.00 (1,100)
Ask (Size) 278.40 (200)
Prev. Close 228.24
Today's Range 223.83 - 229.50
52wk Range 124.06 - 248.60
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know ↗
This agribusiness firm delivers grain, renewables, and plant nutrient solutions to commercial and industrial clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ascendis (ASND) Q4 2025 Earnings Call Transcript ↗
Ascendis (ASND) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+7.5%
+7.5%
1 Month
-4.2%
-4.2%
3 Month
+7.5%
+7.5%
6 Month
+14.1%
+14.1%
1 Year
+50.7%
+50.7%

More News

Read More
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss ↗
Via Chartmill
Topics Earnings
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 12, 2025 ↗
Via Benzinga
News headline image
A Look Ahead: Ascendis Pharma's Earnings Forecast ↗
Via Benzinga
News headline image
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗
Via Chartmill
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Ascendis (ASND) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
Via Benzinga
News headline image
Looking Into Ascendis Pharma AS's Recent Short Interest ↗
Via Benzinga
News headline image
Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis ↗
Via Chartmill
News headline image
What Does the Market Think About Ascendis Pharma AS? ↗
Via Benzinga
News headline image
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
Via Benzinga
News headline image
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Technical Strength and High-Growth Momentum ↗
Via Chartmill

Frequently Asked Questions

Is Ascendis Pharma A/S - American Depositary Shares publicly traded?
Yes, Ascendis Pharma A/S - American Depositary Shares is publicly traded.
What exchange does Ascendis Pharma A/S - American Depositary Shares trade on?
Ascendis Pharma A/S - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Ascendis Pharma A/S - American Depositary Shares?
The ticker symbol for Ascendis Pharma A/S - American Depositary Shares is ASND on the Nasdaq Stock Market
What is the current price of Ascendis Pharma A/S - American Depositary Shares?
The current price of Ascendis Pharma A/S - American Depositary Shares is 229.25
When was Ascendis Pharma A/S - American Depositary Shares last traded?
The last trade of Ascendis Pharma A/S - American Depositary Shares was at 04/02/26 04:00 PM ET
What is the market capitalization of Ascendis Pharma A/S - American Depositary Shares?
The market capitalization of Ascendis Pharma A/S - American Depositary Shares is 13.10B
How many shares of Ascendis Pharma A/S - American Depositary Shares are outstanding?
Ascendis Pharma A/S - American Depositary Shares has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.